Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study.
QuantiFERON
heparin-binding haemagglutinin adhesin
immunomonitoring
inflammatory markers
interferon-gamma release assays
treatment monitoring
tuberculosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
10
2020
accepted:
03
12
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Tuberculosis (TB) is a leading infectious cause of death. To improve treatment efficacy, quicker monitoring methods are needed. The objective of this study was to monitor the response to a heparin-binding hemagglutinin (HBHA) interferon- This multicentered cohort study was based in Bangladesh, Georgia, Lebanon, Madagascar, and Paraguay. Adult, non-immunocompromised patients with culture-confirmed pulmonary TB were included. Patients were followed up at baseline (T0), after two months of treatment (T1), and at the end of therapy (T2). Clinical data and blood samples were collected at each timepoint. Whole blood samples were stimulated with QFT-P antigens or recombinant methylated Between December 2017 and September 2020, 132 participants completed treatment, including 28 (21.2%) drug-resistant patients. rmsHBHA IFN- We showed that QFT-P and rmsHBHA IFN-
Sections du résumé
Background
Tuberculosis (TB) is a leading infectious cause of death. To improve treatment efficacy, quicker monitoring methods are needed. The objective of this study was to monitor the response to a heparin-binding hemagglutinin (HBHA) interferon-
Methods
This multicentered cohort study was based in Bangladesh, Georgia, Lebanon, Madagascar, and Paraguay. Adult, non-immunocompromised patients with culture-confirmed pulmonary TB were included. Patients were followed up at baseline (T0), after two months of treatment (T1), and at the end of therapy (T2). Clinical data and blood samples were collected at each timepoint. Whole blood samples were stimulated with QFT-P antigens or recombinant methylated
Findings
Between December 2017 and September 2020, 132 participants completed treatment, including 28 (21.2%) drug-resistant patients. rmsHBHA IFN-
Conclusion
We showed that QFT-P and rmsHBHA IFN-
Identifiants
pubmed: 33603746
doi: 10.3389/fimmu.2020.616450
pmc: PMC7885528
doi:
Substances chimiques
Antitubercular Agents
0
Biomarkers
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
616450Subventions
Organisme : FIC NIH HHS
ID : D43 TW007124
Pays : United States
Informations de copyright
Copyright © 2021 Chedid, Kokhreidze, Tukvadze, Banu, Uddin, Biswas, Russomando, Acosta, Arenas, Ranaivomanana, Razafimahatratra, Herindrainy, Rakotonirina, Raherinandrasana, Rakotosamimanana, Hamze, Ismail, Bayaa, Berland, De Maio, Delogu, Endtz, Ader, Goletti and Hoffmann.
Déclaration de conflit d'intérêts
MH, MI, and RB had logistic support from the National TB program in Lebanon. DG reports personal fees from Quidel, Qiagen, Janssen, BioMérieux, and Celgene, outside the submitted work. All authors have submitted the ICMJE Form for Disclosure of Potential.
Références
J Clin Microbiol. 2013 Feb;51(2):607-10
pubmed: 23175268
Infect Dis (Lond). 2017 Jun;49(6):474-477
pubmed: 28116958
Am J Respir Crit Care Med. 2007 Aug 15;176(4):409-16
pubmed: 17541018
Int J Environ Res Public Health. 2017 Feb 27;14(3):
pubmed: 28264462
BMC Infect Dis. 2008 Jan 28;8:11
pubmed: 18226199
BMC Public Health. 2017 Mar 20;17(1):269
pubmed: 28320351
PLoS One. 2011 Mar 29;6(3):e18315
pubmed: 21479248
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1145-1149
pubmed: 28911359
PLoS One. 2012;7(8):e43285
pubmed: 22912846
Respirology. 2018 May;23(5):455-466
pubmed: 29457312
BMC Infect Dis. 2011 May 19;11:135
pubmed: 21595874
Infect Immun. 2006 May;74(5):3006-11
pubmed: 16622240
Eur Respir J. 2018 Nov 8;52(5):
pubmed: 30361242
J Clin Microbiol. 2011 Mar;49(3):772-6
pubmed: 21177899
Mem Inst Oswaldo Cruz. 2015 Apr;110(2):235-48
pubmed: 25946248
Immunol Rev. 2015 Mar;264(1):74-87
pubmed: 25703553
Ann Am Thorac Soc. 2016 Dec;13(12):2151-2158
pubmed: 27580246
PLoS Med. 2007 Jul 24;4(7):e238
pubmed: 17676945
Nat Microbiol. 2019 May;4(5):748-758
pubmed: 30804546
Sci Rep. 2018 Oct 23;8(1):15626
pubmed: 30353115
J Infect. 2018 Dec;77(6):526-533
pubmed: 30267797
BMC Med Res Methodol. 2013 Jul 31;13:100
pubmed: 23902644
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1415-1423
pubmed: 28429162
Tuberculosis (Edinb). 2020 Sep;124:101966
pubmed: 32866942
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):303-9
pubmed: 16510310
J Clin Microbiol. 2018 Sep 25;56(10):
pubmed: 30068533
PLoS One. 2007 Oct 03;2(10):e926
pubmed: 17912342
J Infect Dis. 2006 Oct 1;194(7):984-92
pubmed: 16960787
Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7
pubmed: 25216831
Restor Dent Endod. 2017 May;42(2):152-155
pubmed: 28503482
Tuberculosis (Edinb). 2015 Dec;95(6):639-650
pubmed: 26515270
Am J Epidemiol. 2014 Aug 1;180(3):318-24
pubmed: 24966219
Lancet Infect Dis. 2010 Jun;10(6):387-94
pubmed: 20510279
J Infect Dis. 2007 Mar 15;195(6):870-8
pubmed: 17299718
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331040
Int J Infect Dis. 2020 Nov;100:199-206
pubmed: 32920230
Front Cell Infect Microbiol. 2017 Feb 07;7:33
pubmed: 28224118